UNSPSC 51313422: Chlorphenamine tannate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C76H52O46.C16H19CLN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72JT935YTT. European Medicines Agency schedules chlorphenamine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01244MIG. Most nations, for tariff and trade purposes, schedule chlorphenamine tannate under HS 29333999. SMILES:.

UNSPSC 51313422 Chlorphenamine tannate is a Commodity code that nominally identifies a specific antihistamine active pharmaceutical ingredient, yet the recent state and local opportunities posted under this code reveal little activity directly aligned with the ingredient itself. Instead, the solicitations tagged to this code address broader pharmaceutical procurement and drug-management systems—naloxone and drug deactivation equipment, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products distributed through cooperative purchasing arrangements. State and local buying bodies pursuing pharmaceutical supply fall into two categories: individual counties and municipalities (exemplified by Seminole County, Florida) managing targeted health initiatives, and state health and human services departments participating in multistate cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP). The actual procurement work reflects supply-chain coordination for finished pharmaceutical products and ancillary health-system goods rather than acquisition of raw or intermediate chemical ingredients.

Recent opportunities show activity concentrated in Florida and Texas, with multistate cooperative coverage including Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a response deadline of July 26, 2023, as a fixed-fee contract with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement before a formal RFP. The Minnesota Department of Administration's Office of State Procurement administers MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, soliciting manufacturers to supply through three authorized wholesalers with proposals due March 26, 2026 and awards effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness. The code shows limited recent opportunities directly addressing chlorphenamine tannate as a discrete commodity; the postings reflect the broader pharmaceutical distribution and program-support environment into which the ingredient category has been classified.